OncoMatch/Clinical Trials/NCT04301765
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Is NCT04301765 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies testosterone 1.62% gel for hypogonadism, male.
Treatment: testosterone 1.62% gel — This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: chemotherapy
have received or are receiving chemo- and/or radiation therapy
Must have received: radiation therapy
have received or are receiving chemo- and/or radiation therapy
Cannot have received: anabolic agents (testosterone, DHEA, growth hormone)
Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months
Lab requirements
Blood counts
Hematocrit >48% [excluded]
Hematocrit >48%, serum creatinine >2.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgia Cancer Center at Augusta University · Augusta, Georgia
- Brigham and Women's Hospital · Boston, Massachusetts
- Veterans Affairs Puget Sound Health Care System · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04301765 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anabolic agents disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify